Efficacy and safety of AZR-MD-001 selenium sulfide ophthalmic ointment in adults with meibomian gland dysfunction over six months of treatment: A Phase 2, vehicle-controlled, randomized extension trial
AZR-MD-001 (0.5 %) was efficacious in treating signs and symptoms of MGD over six months, with a lower observed incidence of new adverse events over time.
Authors
- Yair Alster
- Charles Bosworth
- Jennifer P. Craig (ORCID: https://orcid.org/0000-0001-8297-5319)
- Laura Elizabeth Downie (ORCID: https://orcid.org/0000-0002-1596-2259)
- Fiona Jane Stapleton (ORCID: https://orcid.org/0000-0002-7203-5443)
- Lyndon Jones (ORCID: https://orcid.org/0000-0002-7409-7349)
- Alison Ng (ORCID: https://orcid.org/0000-0002-6277-8470)
- Jacqueline Tan (ORCID: https://orcid.org/0000-0003-4986-4945)
- Mark Hinds
Institutions
- University of Waterloo (CA)
- University of Auckland (NZ)
- The University of Melbourne (AU)
- Tel Aviv Sourasky Medical Center (IL)
- Australian College of Optometry (AU)
- UNSW Sydney (AU)
- Cancer Trials Australia (AU)
Publication Details
- Journal
- The Ocular Surface
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1016/j.jtos.2024.11.008
- Citations
- 13
- Primary Topic
- Ocular Surface and Contact Lens
- Type
- article
- Field-Weighted Citation Impact
- 7.06